Pulanić, Dražen http://orcid.org/0000-0002-1177-8921
Bátorová, Angelika http://orcid.org/0000-0003-0567-4250
Bodó, Imre http://orcid.org/0000-0003-4170-8577
Červinek, Libor
Ionita, Ioana http://orcid.org/0000-0003-0681-4198
Lissitchkov, Toshko http://orcid.org/0000-0003-2238-8598
Melikyan, Anahit
Podolak-Dawidziak, Maria http://orcid.org/0000-0003-3987-3100
Article History
Received: 7 November 2022
Accepted: 26 January 2023
First Online: 24 February 2023
Declarations
:
: DP received honoraria as a member of advisory boards and/or speaker from Novartis, Amgen, and Sobi; AB received honoraria as a member of advisory boards and speaker from Novartis and Sobi; II received honoraria as a member of advisory boards and/or speaker from Novartis, Amgen, Pfizer, Roche, Takeda, Accord, and Sobi; TL has taken part as a Principle Investigator for projects financed by Bayer, CSL Behring, Catalist, Grifols, Octapharma, Pfizer, Sanofi-Alnilam, and Bioverativ, received honoraria as a member of advisory boards from Roche and Sobi, and has received honoraria as a lecturer from Novo Nordisk, Octapharma, Roche, and Sobi; IB declares no conflicts of interest; LC received honoraria as a member of advisory boards and/or speaker from Novartis, Amgen, Alexion, and Sobi; AM received honoraria as a member of advisory boards from Novartis and Sobi and as a speaker from Novartis and Amgen; and M.P-D has received consulting and lecture fees from Alexion, Amgen, CSL-Behring, Novo Nordisk, Novartis, Orphan, Roche, Sanofi, Sobi, Swiss-Pharma, and Takeda and an institutional research grant from Takeda.